BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

...Mallinckrodt plc (NYSE:MNK) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...sevenfold increase in the price charged by Teva...
...controls. Steve Usdin Mallinckrodt plc Amgen Inc. AbbVie Inc. Novartis AG Johnson & Johnson Teva Pharmaceutical Industries Ltd. Celgene...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

...and is marketed by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA).Committee...
...development of generic competition. The committee said that Teva...
...and free medicines worth billions of dollars.” Teva...
BioCentury | Aug 19, 2020
Product Development

Launch of generic Tecfidera puts more pressure on Biogen’s pipeline

...Deal”). Mylan already markets generic formulations of MS drug Copaxone glatiramer acetate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...FDA-approved generic to Teva’s thrice-weekly formulation in 2017 (see “FDA Approves Mylan’s Generic Copaxone”).On Tuesday, Teva’s...
...filed a complaint in the U.S. District Court for the District of Massachusetts alleging that Teva...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...from partner Sandoz for Glatopa glatiramer acetate, its generic formulation of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Corp. (HSE:ORNAV; HSE:ORNBV) and Eisai Co. Ltd. (Tokyo:4523); Azilect rasagiline mesylate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...to tap its existing commercialization partners for its more advanced OA therapy. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...formed in 2018 with the acquisition of pridopidine, a neuroprotective therapy from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...made its public debut in November (see “Standing Out in the NASH Crowd” ). At Teva...
...Netherlands, and Herzliya, Israel Technology: Pridopidine, a SIGMAR1 agonist Origin of technology: Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...newly created position. He was head of global specialty clinical development at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...is due to read out next half, the partners plan to end the molecule’s development. Teva...
...Austedo China’s National Medical Products Administration (NMPA) has approved Austedo deutetrabenazine from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...for $725 million up front and up to $1 billion in milestones. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
Items per page:
1 - 10 of 2160
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

...Mallinckrodt plc (NYSE:MNK) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...sevenfold increase in the price charged by Teva...
...controls. Steve Usdin Mallinckrodt plc Amgen Inc. AbbVie Inc. Novartis AG Johnson & Johnson Teva Pharmaceutical Industries Ltd. Celgene...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

...and is marketed by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA).Committee...
...development of generic competition. The committee said that Teva...
...and free medicines worth billions of dollars.” Teva...
BioCentury | Aug 19, 2020
Product Development

Launch of generic Tecfidera puts more pressure on Biogen’s pipeline

...Deal”). Mylan already markets generic formulations of MS drug Copaxone glatiramer acetate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...FDA-approved generic to Teva’s thrice-weekly formulation in 2017 (see “FDA Approves Mylan’s Generic Copaxone”).On Tuesday, Teva’s...
...filed a complaint in the U.S. District Court for the District of Massachusetts alleging that Teva...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...from partner Sandoz for Glatopa glatiramer acetate, its generic formulation of Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Corp. (HSE:ORNAV; HSE:ORNBV) and Eisai Co. Ltd. (Tokyo:4523); Azilect rasagiline mesylate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...to tap its existing commercialization partners for its more advanced OA therapy. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...formed in 2018 with the acquisition of pridopidine, a neuroprotective therapy from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
...made its public debut in November (see “Standing Out in the NASH Crowd” ). At Teva...
...Netherlands, and Herzliya, Israel Technology: Pridopidine, a SIGMAR1 agonist Origin of technology: Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...newly created position. He was head of global specialty clinical development at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...is due to read out next half, the partners plan to end the molecule’s development. Teva...
...Austedo China’s National Medical Products Administration (NMPA) has approved Austedo deutetrabenazine from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...for $725 million up front and up to $1 billion in milestones. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA...
Items per page:
1 - 10 of 2160